MPS NEW

Current Neuropharmacology

Journal Impact Factor: 5.3

Scopus Cite Score: 10.0

Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed

View All

Aims and Scope:

Aims and Scope: Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience. The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.

Editor-in-Chief:

Ferdinando Nicoletti Department of Pharmaceutical Sciences
University Rome'da Sapienza'
Rome
Italy

ISSN: 1570-159X (Print)

eISSN: 1875-6190 (Online)

Special Issues With Active Call for Papers

Submission closes on: Jun 07, 2027

Bridging the Gap in Neurotherapeutics: Leveraging Pre-clinical Models and Medical Informatics for Translational Neuroscience

The landscape of neuropharmacology is innovated by computational science. The thematic issue highlights the important focus of artificial intelligence, machine learning, and medical informatics to accelerate clinical translation and pharmaceutical applications for complex neurological disorders. This topic shows how algorithms are applied to maximize patient stratification and target identification through integration of pre-clinical modelling, clinical trials, and big data analysis. A curated selection of bibliometric analyses, comprehensive narrative reviews, systematic reviews, meta-analyses, and original researches... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Woon-Man Kung
Co-Guest Editor(s): Dr. Sunil Kumar,Dr. Yao-Chin Wang

Start Submission

Submission closes on: Jun 06, 2027

Advances in Microglia-induced Neuroinflammation and Neurological Disorders: Mechanisms and Therapeutic Frontiers

This thematic issue provides an in‑depth focus on microglia‑driven neuroinflammation and its pivotal role in a spectrum of neurological disorders, such as ischemic stroke, Alzheimer’s disease, Parkinson’s disease, and chronic pain. Microglia, as the primary immune cells of the central nervous system, dynamically shift between homeostatic and reactive states, releasing a wide array of cytokines, chemokines, and reactive species that profoundly shape disease progression and neuronal fate. The issue aims to bring together original research... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Xing Li
Co-Guest Editor(s): Dr. Qian Xia

Start Submission

Submission closes on: Apr 05, 2027

Advances in Pain Mechanisms and Regulation

This thematic issue focuses on the molecular, cellular and circuit-level mechanisms underlying pain processing and pathogenesis, spanning acute, chronic, neuropathic and cancer pain. It highlights novel regulatory pathways (e.g., mitochondrial function, ion channel signaling) and key cellular subsets (e.g., PV⁺ interneurons) that govern pain sensitization and persistence. We aim to showcase cutting-edge mechanistic studies, translational research and emerging therapeutic targets, bridging basic neuroscience and clinical pain management. This collection will provide a comprehensive update for... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Ya-Qun Zhou
Co-Guest Editor(s): Dr. Daiqiang Liu

Start Submission

Submission closes on: Feb 08, 2027

MicroRNA-Driven Neurogenomic Reprogramming: Next-generation Therapeutic Strategies for Neurodegenerative Disorders

Neurodegenerative diseases are caused by the gradual breakdown of neurons and depend on cumulative factors, such as genetics and environment; therefore, neurodegenerative diseases continue to create extensive impairment of neural networks and disruption of their function. microRNAs represent a class of new mechanisms of gene regulation that have been shown to regulate gene expression post-transcriptionally and/or induce large-scale changes in the neurogenomic program. Evidence now suggests that dysregulation of microRNA expression may lead to changes... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Krishnendu Adhikary
Co-Guest Editor(s): Dr. Mohamed Abubakar,Dr. Nitesh Kumar

Start Submission

Submission closes on: Nov 06, 2026

Current Trends in Application of Large Language Models in Intelligent Medicine and Healthcare particularly neurodegenerative disorders

In this era of modern technology, there has been advanced progress in integrating artificial intelligence in chemoinformatics to accelerate the discovery of neurotherapeutics from natural and synthetic sources. This special issue could explore how AI-driven chemoinformatic tools are revolutionising the identification, profiling, and optimisation of bioactive compounds for the treatment of neurological diseases such as Alzheimer’s, Parkinson’s, epilepsy, and multiple sclerosis. Contributions could include machine learning models for predicting neuroactivity, virtual screening of natural product... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Mohammad Amjad Kamal
Co-Guest Editor(s): Prof. Bairong Shen,Nigel H. Greig

Start Submission

Submission closes on: Oct 31, 2026

Advances in Neuroimaging: Bridging Pharmacology, Nanotechnology, and Neurological Disorders

This special topic seeks to compile cutting-edge research and reviews that explore the synergy between neuroimaging, pharmacology, and nanotechnology in understanding and treating neurological disorders. We aim to elucidate novel imaging biomarkers for tracking drug efficacy and disease progression in conditions such as Alzheimer’s, Parkinson’s, multiple sclerosis, and brain tumors. Highlight nanomaterial innovations (e.g., quantum dots, dendrimers, lipid nanoparticles) for improved imaging resolution, targeted or minimally invasive theranostics. Address neurotrauma applications, including imaging-guided interventions for... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Jianhua Liu
Co-Guest Editor(s): Dr. Yang Liu,Dr. Yinghui Wang

Start Submission

Submission closes on: Oct 24, 2026

Plant-derived extracellular vesicles in brain aging and neurodegenerative diseases

Plant-derived extracellular vesicles (PDEVs) have recently emerged as both promising natural compounds and nanocarriers in the field of brain aging and neurodegenerative diseases. Owing to their biocompatibility, low immunogenicity, and intrinsic bioactive cargo, PDEVs offer an alternative drug delivery system. Increasing evidence suggests that PDEVs can easily cross biological barriers, including the blood-brain barrier, modulate oxidative stress, inflammation, and cellular senescence, addressing key pathological mechanisms underlying brain aging and neurodegenerative diseases. Beyond their therapeutic applications,... see more

Impact Factor: 5.3
Guest Editor(s): Metehan Uzun
Co-Guest Editor(s): Damla Aykora,Yıldızhan Şengül

Start Submission

Submission closes on: Oct 03, 2026

New Approaches in Brain Injury and Neurodegenerative Disease: Converging Mechanisms and Therapeutic Frontiers

Brain injury and neurodegenerative diseases represent a continuum of neurological dysfunction marked by progressive cellular damage, impaired neuroplasticity, and cognitive decline. Although traditionally considered distinct, mounting evidence reveals shared pathophysiological mechanisms—including oxidative stress, mitochondrial dysfunction, excitotoxicity, and chronic neuroinflammation—that contribute to both acute and chronic neural deterioration. This special issue explores both the underlying mechanisms driving brain injury and neurodegeneration, and the innovative therapeutic strategies aimed at halting or reversing their progression. Topics include emerging... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Francisco Capani
Co-Guest Editor(s): Juan Pablo Luaces

Start Submission

Submission closes on: Aug 21, 2026

Emerging Concepts in Mechanisms and Therapeutic Strategies for CNS Demyelinating Diseases

We are pleased to invite submissions for this special issue titled "Emerging Concepts in Mechanisms and Therapeutic Strategies for CNS Demyelinating Diseases." This issue aims to highlight recent advances in the understanding and management of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Although several FDA-approved disease-modifying therapies have significantly reduced relapse rates and radiologic activity in MS, therapeutic strategies targeting... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Smathorn Thakolwiboon
Co-Guest Editor(s): Dr. Pei Shang,Dr. Nisa Vorasoot

Start Submission

Submission closes on: Aug 13, 2026

Neuropharmacology of Psychedelics

Classical psychedelics are driving a renewed effort to connect receptor-level pharmacology with circuit dynamics and therapeutic models. Foundational research and human pharmacology establish 5-HT2A signaling as central to their acute effects and candidate mechanisms of action. Recent randomized trials report clinically meaningful symptom reductions with psilocybin in treatment-resistant depression and with MDMA-assisted therapy in moderate-to-severe PTSD, motivating careful attention to efficacy, safety, and reproducibility. Converging preclinical and human studies indicate that these agents promote structural... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Mehmet Bostancıklıoglu

Start Submission

Submission closes on: Jul 25, 2026

Advances in Neurovascular Unit in Stroke and Neurodegenerative Disease: Mechanisms and Therapeutic Frontiers

The main goal of this special issue is to analyze current knowledge of the functional roles of various types of cells in neurovascular units(NVU) in neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. This issue invites research on the cellular and molecular mechanisms driving inflammation, blood-brain barrier(BBB) injury, oxidative stress response, autophagy, apoptosis, and necrosis in NVU. In addition, the topic seeks to emphasize therapeutic strategies aimed at regulating these mechanisms to protect... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Changxiang Li
Co-Guest Editor(s): Dr. Yang Liu,Dr. Xueqian Wang,Dr. Qingguo Wang,Dr. Xiaoyu Xu

Start Submission

Submission closes on: Jul 03, 2026

Advances and Integrative Approaches to Gut-Brain Interactions

Disorders of gut-brain interaction (DGBIs), formerly known as functional gastrointestinal disorders, involve dysfunction of complex signaling pathways between the gastrointestinal tract and the central nervous system. These disorders span the esophagus (functional heartburn, functional dysphagia), stomach (functional dyspepsia), and intestines (irritable bowel syndrome, chronic constipation), and are increasingly recognized as multisystem syndromes influenced by neural, immune, endocrine, and microbial factors. Emerging neuropharmacological evidence highlights novel pharmacological therapies, neuromodulation, behavioral interventions, and integrative medicine approaches as... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Tao Bai
Co-Guest Editor(s): Dr. Runze Quan,Dr. Gengqing Song

Start Submission

Submission closes on: Jun 30, 2026

Cannabinoids in Health and Disease.

The role of cannabinoids in human physiology and disease has become a dynamic and rapidly evolving field of research, offering new insights into the potential of these compounds. With advancements in neuropharmacology and clinical trials, cannabinoids are now at the forefront of innovative approaches to treat several conditions. This special issue aims to bring together cutting-edge research and comprehensive reviews that explore the multifaceted role of cannabinoids in different pathophysiological contexts. The focus will be... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Rui Rodrigues
Co-Guest Editor(s): Dr. Ana Covelo,Dr. Livio Luongo

Start Submission

Submission closes on: Jun 22, 2026

Chinese Multidisciplinary Expert Consensus on the Neurotherapeutics: from Neurodegenerative Diseases to Cerebral Vascular Disease

Besides the excellent fields of science, humanities, aerospace, military, technology, industry, Clinical Neuroscience, as well as Neurology in China, have also made huge progress in the world. Therefore, the Special Issue Editor, would assume that it is deserved to organize Chinese Multidisciplinary Expert Consensus’ series on Neurology, especially in Neuropharmacology advances and clinical experience, following the paper of Chinese Multidisciplinary Expert Consensus on Orphan/Anticopper Drugs and Other Non-drug Management of Hepatolenticular Degeneration ( Wang XP…)... see more

Impact Factor: 5.3
Guest Editor(s): Dr. Xiao Ping Wang

Start Submission